TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02245971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial precutting
Description: Partial precutting will be performed prior to dissection during the ESD.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole precutting
Description: Whole precutting will be performed prior to dissection during the ESD.
Study: NCT01828476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
Study: NCT00613964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carperitide heart failure therapy
Description: carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard heart failure therapy
Description: Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
Study: NCT03246698

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: They will receive only standard physiotherapy program, four times a week for four weeks, 15 sessions in total.
Study: NCT02386592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG)
Description: All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
Study: NCT03398005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 x 1 g capsules administered orally once a day for 26 weeks
Study: NCT00152776

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ovaria comp 10 globuli 3 times per day 24 weeks
Description: order of intervention and placebo varies between Groups I-III
Study: NCT02386592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene (HH)
Description: Alcohol hand rub will be produced in the hospital pharmacy and will be readily available in the NICU (via wall-mounted dispensers) throughout the intervention period. Hand hygiene among NICU physicians and nurses will actively be promoted through the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infection control training
Description: All NICU healthcare workers will receive infection prevention training which will involve structure training on HH, universal precautions, neonatal skin antisepsis and peripheral IV placement and line care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infection control reminders via SMS text
Description: Infection control practice reminders will be sent to NICU healthcare workers on a daily basis via SMS messages.
Study: NCT00873210

Intervention type: DRUG
Intervention: Sutent
Description: 50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
Study: NCT03215485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition lessons
Description: Face-to-face interactive group lessons delivered in the classroom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual world learning environment
Description: Every participant has their own unique avatar in the virtual world learning environment named Rippleville. They can choose to complete quests, watch archived nutrition video lessons, explore, and socialize with other avatars. They receive rewards (Rippleville dollar and badges) for their efforts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter
Description: All participants in the intervention and comparison groups receive up to 10 professional newsletters on topics related to sports nutrition and performance, healthy eating and active living tips.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newsletter
Description: All participants in the intervention and comparison groups receive up to 10 professional newsletters on topics related to sports nutrition and performance, healthy eating and active living tips.
Study: NCT00603343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mictonetten 5 mg, coated tablet
Description: propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo corresponding to body weight
Study: NCT00152776

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ovaria comp 10 globuli 3 times per day 24 weeks
Description: order of intervention and placebo varies between Groups I-III

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ovaria comp 10 globuli 3 times per day 24 weeks
Description: order of intervention and placebo varies between Groups I-III
Study: NCT02911883

Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography
Study: NCT01828476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
Study: NCT04609254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
Study: NCT03924596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)
Description: AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma
Study: NCT04609254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
Study: NCT01217073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
Study: NCT03924596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)
Description: AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Sodium Hydrogen Citrate
Description: Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Sodium Hydrogen Citrate
Description: Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)
Study: NCT01039597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORE1001
Description: Oral capsules containing 300 mg of the active, study drug
Study: NCT01217073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
Study: NCT01848912

Intervention type: DEVICE
Intervention: Zephyr Biopatch Device
Study: NCT01217073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 mg oral tablet or capsule administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg oral tablet administered once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to metformin
Description: Matching placebo to metformin oral tablet administered once daily
Study: NCT02301143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Study: NCT02301143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical intervention
Study: NCT03555396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Couples 2
Description: The intervention will consist of 4 sessions with activities designed to strengthen communication and support within the couple to improve adherence to antiretroviral therapy and increase linkage to drug treatment services. The activities are based on cognitive-behavioral therapy. Participants' adherence will be monitored continuously through electronic monitoring devices and surveys completed at baseline and follow-up periods.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care consists of an appointment with an AIDS Center nurse at baseline and two months later. Under current Standard of Care in Almaty, no behavioral intervention is provided. Participants obtain prescription refills and give blood for viral load and CD4 tests once every 6 months.
Study: NCT02647658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline Based Care plus Psychologically Informed Physical Therapy
Description: PCP care is enhanced with a prompt referral to physical therapy (PT) that includes psychologically informed coaching directed towards education and reduced fear of movement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Based Care (GBC)
Description: Management decisions are made between PCPs and patients with the guidance of best evidence but with no specific directives
Study: NCT02194426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0250
Description: Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
Study: NCT05944419

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant surgery
Description: Placement of immediate implant and immediate provisionalization after tooth extraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant surgery
Description: Placement of immediate implant and immediate provisionalization after tooth extraction
Study: NCT02015117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of the tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo whole-brain radiation therapy
Study: NCT03814889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibration pattern
Description: Vibration patterns applied to the affected limb based on pilot study results.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibration pattern
Description: Vibration patterns applied to the affected limb based on pilot study results.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No vibration
Description: These patients will wear a glove with a blinking light instead of feeling vibrations.
Study: NCT01039597

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules
Study: NCT01604499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback letters
Description: Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback plus incentives
Description: Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
Study: NCT00354523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Description: Starting Dose 500 mg/m\^2 twice a day Days 1-14 of 21 Day Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC-Dome (Dacarbazine)
Description: Starting Dose 250 mg/m\^2 a day on Days 1-3 of 21 Day Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec (Imatinib Mesylate)
Description: Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
Study: NCT00695903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: daptomycin 10 mg/kg IV every 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
Study: NCT00484705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical exercise

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Untreated control
Study: NCT00270218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA009-00-VP
Description: HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FFB
Description: Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FFB
Description: Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PBS
Description: phosphate buffered saline
Study: NCT01863277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04447404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT03174223

Intervention type: DRUG
Intervention: deep neuromuscular block
Description: a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
Study: NCT02501343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Oral Capsule
Description: Sodium bicarbonate 1680 mg will be administered prior to the meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
Study: NCT02123654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Study: NCT02067000

Intervention type: BEHAVIORAL
Intervention: Obstructive Sleep Apnea
Description: Questionnaire about CPAP perceptions
Study: NCT03942861

Intervention type: DRUG
Intervention: Solu-Medrol
Description: Standard treatment according to Danish Guidelines for acute severe ulcerative colitis.
Study: NCT03068676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Depression
Description: internet-delivered CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Anxiety
Description: internet-delivered CBT
Study: NCT00095251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
Study: NCT03085082

Intervention type: DIAGNOSTIC_TEST
Intervention: blood type test
Description: a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups

Intervention type: DIAGNOSTIC_TEST
Intervention: blood type test
Description: a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups

Intervention type: DIAGNOSTIC_TEST
Intervention: blood type test
Description: a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups
Study: NCT01753479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spectroscopy device
Description: Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
Study: NCT03117673

Intervention type: OTHER
Intervention: transesophageal echocardiography measurements
Description: transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity
Study: NCT02581579

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
Description: Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 capsule per day during 14
Study: NCT02948751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoCEE
Description: The CSF sample will be to delivered to Biocept's laboratory for processing, and it will be evaluated for CTCs using OncoCEETM microchannel technology. This CSF sample will also be tested for cell-free circulating tumor DNA (ctDNA).
Study: NCT02123654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for DCV 3DAA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for Daclatasvir

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for Asunaprevir
Study: NCT00738777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg,QD,PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole+Fulvestrant
Description: Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
Study: NCT03117673

Intervention type: OTHER
Intervention: transesophageal echocardiography measurements
Description: transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity

Intervention type: OTHER
Intervention: transesophageal echocardiography measurements
Description: transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity
Study: NCT00743691

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Based
Description: In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
Study: NCT03607630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting
Description: psychological therapy
Study: NCT00738777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Description: loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
Study: NCT02173249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC 170 0.24%
Description: 1 drop in each eye 2 times daily for 1 week